Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Cancer. 2011 Feb 11;117(15):3383–3392. doi: 10.1002/cncr.25939

Table 3.

CYP19 exon I.6 genotype (rs10459592) and HBV/HCV status in relation to risk of hepatocellular carcinoma (HCC), the Los Angeles County and Guangxi case-control studies

CYP19 I.6 genotype Los Angeles Guangxi Total
CA/COa OR (95% CI)b CA/COa OR (95% CI)b CA/COa OR (95% CI)c
HBV and HCV negative
AA 9/40 1.00 14/76 1.00 23/116 1.00
AC 32/86 1.75 (0.73–4.19) 19/97 1.14 (0.52–2.52) 51/183 1.37 (0.77–2.44)
CC 22/41 2.79 (1.07–7.24) 11/33 2.14 (0.82–5.55) 33/74 2.25 (1.18–4.31)
P for trend 0.032 0.150 0.014
HBV or HCV positive
AA 10/3 1.00 78/9 1.00 88/12 1.00
AC 50/18 1.20 (0.21–6.74) 91/18 0.50 (0.21–1.21) 141/36 0.61 (0.29–1.30)
CC 12/5 1.17 (0.15–9.28) 31/9 0.33 (0.11–0.94) 43/14 0.48 (0.20–1.19)
P for trend 0.905 0.032 0.107
a

CA/CO, number of cases/number of controls.

b

Adjusted for age, sex, race/ethnicity, level of education, number of cigarettes smoked per day and number of alcoholic drinks per day.

c

Additionally adjusted for study location